Literature DB >> 18339360

In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist.

Koen Van Laere1, Guy Bormans, Sandra M Sanabria-Bohórquez, Tjibbe de Groot, Patrick Dupont, Inge De Lepeleire, Jan de Hoon, Luc Mortelmans, Richard J Hargreaves, John R Atack, H Donald Burns.   

Abstract

BACKGROUND: A novel, high-affinity (.7-2.0 nmol) compound that selectively activates the alpha2, alpha 3, and alpha 5 (but not alpha1) gamma-aminobutyric acid-A (GABA(A)) receptor subtypes, TPA023B (2',6-difluoro-5'-[3-(1-hydroxy-1-methylethyl) imidazo[1,2-b][1,2,4]triazin-7-yl][1,1'-biphenyl]-2-carbonitrile) was pharmacologically characterized and studied by means of positron emission tomography (PET) to determine dynamic occupancies of the benzodiazepine binding site of human brain GABA(A) receptors after a single oral dose.
METHODS: Four healthy male volunteers were studied in a double-blind, randomized placebo-controlled study of which three were given a single dose of 1.5 mg TPA023B and the fourth received placebo. The time course of GABA(A) receptor occupancy was determined with multiple dynamic [(11)C]flumazenil PET studies at pre-dose baseline and 5 and 24 hours after dose. Arterial sampling and full kinetic modeling with a two-compartment model was used to calculate parametric maps of receptor availability (distribution volume V(T)) and of occupancy.
RESULTS: The GABA(A) receptor occupancy as determined from [(11)C]flumazenil V(T) values in all brain regions was reduced homogeneously, on average by 52.5 +/- 1.2% after 5 hours and 46.4 +/- 6.0% after 24 hours. No serious adverse events were encountered in humans.
CONCLUSIONS: Single oral doses of 1.5 mg of TPA023B correspond to average receptor occupancies in neocortical regions of 52% and 46% after 5 and 24 hours, respectively. Provided suitable ligands and quantification methods are available for the appropriate target, quantitative PET offers a unique tool for dynamic in vivo measurement of relevant on-site receptor occupancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339360     DOI: 10.1016/j.biopsych.2008.01.021

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  5 in total

Review 1.  Imaging the role of GABA in movement disorders.

Authors:  Henning Boecker
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

2.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

3.  Age-related GABAergic differences in the primary sensorimotor cortex: A multimodal approach combining PET, MRS and TMS.

Authors:  Koen Cuypers; Melina Hehl; June van Aalst; Sima Chalavi; Mark Mikkelsen; Koen Van Laere; Patrick Dupont; Dante Mantini; Stephan P Swinnen
Journal:  Neuroimage       Date:  2020-11-10       Impact factor: 6.556

4.  Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients.

Authors:  Charlotte D'Hulst; Inge Heulens; Nathalie Van der Aa; Karolien Goffin; Michel Koole; Kathleen Porke; Marc Van De Velde; Liesbeth Rooms; Wim Van Paesschen; Hilde Van Esch; Koen Van Laere; R Frank Kooy
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

5.  The α2/α3GABAA receptor modulator TPA023B alleviates not only the sensory but also the tonic affective component of chronic pain in mice.

Authors:  Elena Neumann; Laura Küpfer; Hanns Ulrich Zeilhofer
Journal:  Pain       Date:  2021-02-01       Impact factor: 7.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.